Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease

This publication has 11 references indexed in Scilit:

• Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination
  Proceedings of the National Academy of Sciences, 2010
• WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy
  Japanese Journal of Clinical Oncology, 2010
• Biased usage of BV gene families of T‐cell receptors of WT1 (Wilms’ tumor gene)‐specific CD8⁺ T cells in patients with myeloid malignancies
  Cancer Science, 2010
• Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
  Journal of Clinical Oncology, 2009
• A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
  Blood, 2009
• Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
  Blood, 2008
• Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
  Proceedings of the National Academy of Sciences, 2004
• Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity
  Leukemia, 2003
• The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia
  Blood, 2003
• Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues
  Cancer Immunology, Immunotherapy, 2002